Just wondering why is there a need for the vaccine to be delivered this way
when there are already other alternatives in the wild and done via
these sprays for instance. Well as you know our vaccine currently
fighting against a Covid-19 only prevent severe diseases is never really made.
It can block the transmission. And since you know the outbreaks there
are a lot of conversation regarding how we can preventing the transmission.
And the one of the method is the mucosal immunization.
And luckily we have spent many years working on this technology.
We're thrilled that our effort is being recognized.
And in fact our held Covid-19 vaccine is the word first.
How will the vaccine be approved for use.
Talk to us about some of the challenges you faced in developing this vaccine.
Well it is not an easy task. As I mentioned we have spent many years
working on this one starting from the other airborne disease such like that to
the closest we have to figure out how precisely the vaccine could deliver to
people and to stimulate not antibody response not only the cell media immune
response but also the meal causal immune response.
As you know the more disease of a virus can get into a human body through the
airways. If we can put the first layer of the
defense system in the airways if you factually block the transmission then we
can effectively and stop the virus circulating in people.
And of course that will have less chance of further mutation.
So I think that's the hope for us to you know eventually end the pandemic through
the certainly closing organization. Your is a shot in Hong Kong.
What is the efficacy of this vaccination.
Have you done any trials on that. What do you look at.
Is it Babs as effective as it be a sign of that that's used here in Hong Kong
for instance. Well we haven't done the clinical trials
for our injectable vaccines which is already applied.
Cho approved for emergency use of the state and the global efficacy trial for
injectable vaccine has demonstrated our vaccine will have over sixty five run
sixty five percent. Advocacy only by single dose and the
immune response which means that the antibody tighter and so media immune
response would be the major artery betterment of the efficacy.
Certainly we are using. You held the vaccine to compare to our
efficacy trial for at least you know from from the immune response
perspective. So we only use 20 percent of our
injectable vaccine sorting. How rude.
Very well actually. Give us like a comparable
antibody and sell me the immune response on top of those.
We also provide mucosal very good mucosa immune response such that such as that
the IJA immune response which adding a certain layer of protection.
So that's what we see. You know the I would say from the last
trial we have done so far over 10 solid subjects.
We do see at least a comparable immune response.
And the plus David Cole the immune response.
So we are expecting the efficacy would be at least comparable or even better
than our jack but was. Okay so when one looks at the efficacy
here know it doesn't stand as well as some of these MRI or any vaccines that
you're developing a candidate. With regards to that particular type of
immunization where are you with that. And secondly would that also then Babs
morph into something which would be inhaled.
Well our MRI vaccine currently is in phase two clinical trial.
We also worked on the MRI technology platform for many years.
Of course the we believe the viral factor was especially through the
inhalation would be the best way so far. And
we will see how this will roll out. As I assume you are already aware that
government approved for the emergency use and then we will see how the
efficacy will be. And also I don't think the MRI
technology so far by the current conventional you know the formulation
we'll be able to stimulate because our immune response.
So we have no plan to use the current formulation of MRI in the Kosovo
delivery route. Shuffling in your estimate when do you
think. How early do you think we'll see that
MRI any vaccine in China. So far all candidates have been pretty
unsuccessful. Well I wouldn't be able to give that
estimation but I think our Phase 2 clinical trials so far as moving very
well and was oh this are you know that how we see I think our
safety profile certainly is very good and we're looking forward to see the
final results when this is ready. Treasurer we're looking at your stock
price. Can Sino trading down about 70 percent
yet today. I mean it does seem like investors are
not really buying into the story. Are they underestimating the potential
of the company. Well certainly you know we're not the
only Covid-19 vaccine producer. We have our very rich applies.
As you may aware we recently launched a quarter Vaillant meningococcal conduit
vaccine which is the first one in Chinese market.
And we're also talking to the international players and partners.
You and Dr. Cho for both our Covid-19 and indeed
Coco kind of get the vaccine for the international market.
And we also have for a very large pipeline through the new pneumococcal
diseases and pediatric combo vaccines. I think we certainly you know how for
high potential we'll be one of the major players in the vaccine field.
Now shift we've seen a lot of places going to lock down and a lot of people
of course have been vaccinated in China. But the thing is the rapid rate of that
vaccination program has also created a lot of people who need to be paid and
you in that position as well. Well as you know the current vaccination
program is supported by the government health funds.
We don't see the policy will change.
And certainly you know we do whatever we can do.
Our goal is to really stop the pandemic. I think people deserve a normal life and
economic deserve no more growth. And the we do whatever we can do.